MarketCapExport financials
Pieris Pharmaceuticals (PIRS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Pieris Pharmaceuticals Income Statement 2025-2011 | PIRS
Brief overview of financial results at Pieris Pharmaceuticals
The overview follows changes across a five-year period. Revenue reported by Pieris Pharmaceuticals was $29.1 million at the beginning of the period and $42.8 million at the end. The cumulative result was +47.1%, corresponding to roughly 8% per year. The direction is positive, but the growth rate is not particularly high.
EBITDA was −$30.3 million at the beginning and −$10 million at the end of the period (+67.1%). EBITDA expanded faster than the top line. EBITDA margin was −104% at the start and −23.3% at the end. The business generated more EBITDA from each unit of revenue.
Net income moved from −26.8 million dollars at the start to 18.7 million dollars at the end. The return to profit marks a meaningful recovery in the final result.
Over the period, capitalization shifted from $141 million to $319 thousand (−99.8%). Investors remain cautious despite better financial results.
Financial takeaway
The five-year picture requires weighing both strengths and weaknesses. The strongest signals are revenue expansion, improving net profitability and an improving EBITDA margin. The main areas of concern are a weaker market valuation and a low EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Pieris Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 30.3 M | 319 K | 91.2 M | 244 M | 138 M | 185 M | 141 M | 335 M | 88 M | 59.5 M | - | - | - | - |
Shares |
11.3 M | 2.23 M | 1.77 M | 74.2 M | 64.5 M | 54.3 M | 50.6 M | 53.1 M | 43.9 M | 41.7 M | 34.4 M | 6.1 M | 5 M | - | - |
Historical Prices |
- | 13.6 | 0.18 | 1.23 | 3.78 | 2.5 | 3.62 | 2.66 | 7.55 | 1.41 | 2.29 | - | - | - | - |
Net Income |
-41.7 M | -17.4 M | 18.7 M | -33.3 M | -45.7 M | -37.2 M | -25.5 M | -26.8 M | -17.6 M | -22.8 M | -14.1 M | -9.85 M | 66.2 K | - | - |
Revenue |
- | - | 42.8 M | 25.9 M | 31.4 M | 29.3 M | 46.3 M | 29.1 M | 25.3 M | 5.83 M | 2.93 M | 5.37 M | 12.4 M | - | - |
Gross Profit |
- | - | - | - | - | 29.3 M | - | - | - | - | 2.93 M | - | - | - | - |
Operating Income |
-38.6 M | -14.1 M | -11.9 M | -43.5 M | -51.8 M | -33.9 M | -27.2 M | -30.8 M | -14.6 M | -22.8 M | -13.7 M | -7.2 M | 554 K | - | - |
Interest Expense |
727 K | -131 K | 712 K | 1.3 M | 2.4 M | -3.66 M | -26 K | 1.8 M | -2.1 M | 120 K | 10.9 K | 2.65 M | 494 K | - | - |
EBITDA |
-38.6 M | -14.1 M | -9.96 M | -40.7 M | -49.4 M | -31.6 M | -26.1 M | -30.3 M | -14.2 M | -22.4 M | -13.4 M | -6.83 M | 939 K | - | - |
Operating Expenses |
38.6 M | 14.1 M | 11.9 M | 69.4 M | 83.2 M | 63.2 M | 73.4 M | 59.9 M | 39.9 M | 28.6 M | 16.6 M | 12.6 M | 274 | - | - |
General and Administrative Expenses |
15.8 M | 5.94 M | 3.08 M | 16.4 M | 16.6 M | 16.7 M | 18.4 M | 18.4 M | 17.6 M | 8.89 M | 8.37 M | 6.96 M | 2.46 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Pieris Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
14.5 M | 14.4 M | 13.1 M | 207 K | 11.1 M | 11.1 M | 11 M | 456 K | 1.77 M | 1.77 M | 1.77 M | 681 K | 1.24 M | 1.1 M | 931 K | 92 K | 74.4 M | 74.1 M | 73.7 M | 2.53 M | 67.7 M | 61.9 M | 56.3 M | 505 K | 54.3 M | 52.4 M | 55.2 M | 820 K | 49.4 M | 49.2 M | 50.9 M | 360 K | 54.1 M | 54 M | 50 M | 307 K | 44.4 M | 43.4 M | 43.1 M | 43.1 M | 43.1 M | 40.9 M | 39.8 M | 1.81 M | 38.9 M | 29.4 M | 29.3 M | 29.3 M | 6.25 M | 5 M | 5 M | 5 M | 6.1 M | 5 M | - | - | - | - | - | - | - | - | - |
Net Income |
-24.6 M | -21.9 M | -15.8 M | -12.7 M | -11.3 M | -9.47 M | -8.18 M | -3.37 M | -6.97 M | -4.37 M | -2.54 M | - | -10.8 M | 3.98 M | -13.2 M | -8.1 M | -9.74 M | -10.3 M | -5.1 M | -9.53 M | -16.5 M | -15.5 M | -4.17 M | -14.4 M | -14.3 M | -4.95 M | -3.6 M | -3.6 M | -2.59 M | -11.8 M | -10.3 M | -11.7 M | -6.15 M | -203 K | -8.71 M | 7.49 M | -7.06 M | -10.1 M | -7.99 M | - | -6.2 M | -5.88 M | -4.16 M | -2.9 M | -3.92 M | -3.53 M | -3.7 M | - | -2.02 M | -2.2 K | -13.9 K | -2.2 K | -5.76 K | -7.96 K | - | - | - | - | - | - | - | - | - |
Revenue |
- | - | - | - | - | - | - | - | - | - | 53 K | 1.05 M | 15.6 M | 20.1 M | 1.94 M | 5.71 M | 5.11 M | 3.47 M | 11.2 M | 7.75 M | 2.78 M | 2.54 M | 14.9 M | 1.52 M | 2.58 M | 10.9 M | 8.88 M | 5.1 M | 14.5 M | 4.93 M | 7.53 M | 4.71 M | 7.87 M | 11.2 M | 3.44 M | 18.2 M | 3.93 M | 1.85 M | 1.34 M | - | 785 K | 1.07 M | 1.25 M | 2.14 M | 415 K | 160 K | 218 K | - | 18.7 K | 698 K | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-22.7 M | -21.4 M | -14.9 M | -11.3 M | -10.2 M | -9.25 M | -7.87 M | -4.37 M | -5.06 M | -2.91 M | -1.76 M | 13.4 M | -11.8 M | 2.06 M | -15.5 M | -11.5 M | -12.2 M | -12.3 M | -7.46 M | -11 M | -19 M | -16.8 M | -5.06 M | -12.4 M | -13 M | -4.66 M | -3.86 M | -1.33 M | -2.91 M | -12.2 M | -10.7 M | -12.6 M | -7.8 M | -2.24 M | -8.14 M | 6.49 M | -5.18 M | -7.89 M | -8.01 M | - | -6.18 M | -5.8 M | -4.38 M | -2.57 M | -3.88 M | -3.53 M | -3.7 M | - | -1.84 M | -2.2 K | -13.9 K | -2.2 K | -5.76 K | -7.96 K | - | - | - | - | - | - | - | - | - |
Interest Expense |
2.55 M | 1.96 M | 1.07 M | 520 K | 628 K | 690 K | 752 K | 281 K | 187 K | -86 K | 171 K | 424 K | 506 K | -161 K | -57 K | -325 K | 723 K | 676 K | 229 K | 378 K | 678 K | 464 K | 884 K | -1.83 M | -1.34 M | -424 K | -60 K | 177 K | -55 K | 23 K | -171 K | 331 K | 1.15 M | 1.23 M | -903 K | 995 K | -1.73 M | -1.38 M | 12 K | - | -18.2 K | -87.8 K | 220 K | - | -1.93 K | 53 | 769 | - | 148 | 114 K | 109 K | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-22.7 M | -21.4 M | -14.9 M | -11.3 M | -10.2 M | -9.25 M | -7.87 M | -4.37 M | -5.06 M | -2.91 M | -1.79 M | 13.4 M | -11.1 M | 2.06 M | -14.9 M | -11.4 M | -11.4 M | -11.7 M | -6.61 M | -11 M | -17.2 M | -16.8 M | -5.06 M | -12.4 M | -13 M | -4.12 M | -3.52 M | -1.1 M | -2.76 M | -12.2 M | -10.5 M | -12.5 M | -7.67 M | -2.1 M | -8 M | 6.59 M | -5.13 M | -7.78 M | -7.91 M | - | -6 M | -5.81 M | -4.29 M | -2.49 M | -3.65 M | -3.38 M | -3.62 M | - | -1.56 M | 187 K | 81.6 K | -2.2 K | -5.76 K | -7.96 K | - | - | - | - | - | - | - | - | - |
Operating Expenses |
22.7 M | 21.4 M | 14.9 M | 11.3 M | 10.2 M | 9.25 M | 7.87 M | 4.37 M | 5.06 M | 2.91 M | 1.76 M | -54.9 M | 31.3 M | 18 M | 17.4 M | 17.4 M | 17.5 M | 16 M | 18.4 M | 19.4 M | 23.1 M | 20 M | 20.7 M | 14.3 M | 15.9 M | 15.9 M | 17.1 M | 18.6 M | 18 M | 17.6 M | 19.2 M | 17.6 M | 16.1 M | 13.9 M | 12.3 M | 11.7 M | 9.11 M | 9.74 M | 9.35 M | - | 6.96 M | 6.87 M | 5.63 M | 4.7 M | 4.29 M | 3.69 M | 3.92 M | - | 1.86 M | 2.2 K | 13.9 K | 2.2 K | 5.76 K | 7.96 K | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
11.9 M | 8.93 M | 5.52 M | 4.18 M | 3.65 M | 4.13 M | 3.8 M | 1.82 M | 1.88 M | 1.47 M | 775 K | -11.4 M | 6.84 M | 3.66 M | 4.02 M | 3.98 M | 3.95 M | 4.08 M | 4.38 M | 4.08 M | 4.13 M | 4.25 M | 4.13 M | 3.67 M | 4.12 M | 4.57 M | 4.36 M | 4.48 M | 4.84 M | 4.19 M | 4.93 M | 4.56 M | 4.75 M | 4.78 M | 4.35 M | 6.39 M | 2.85 M | 4.35 M | 3.99 M | - | 2.34 M | 2.37 M | 1.97 M | 1.76 M | 2.24 M | 1.97 M | 2.39 M | - | 933 K | 2.35 M | 18 | - | 12 | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Pieris Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Niderland
Israel
Spain
Germany
Australia
Britain
